Dear Provider,
The national supply chain shortage of the nirsevimab products (Sanofi and AstraZeneca), Beyfortus 100mg (NDC: 49281-0574-15) and Beyfortus 50mg (NDC: 49281-0575-15), will continue to have large ramifications on available doses through the State Vaccine Program moving forward. Sites will not be able to request additional doses of either nirsevimab product through the MIIS during this ordering shutdown which will continue thru the end of this RSV season.
The Department of Public Health has been informed that we will receive a limited supply of additional doses of Beyfortus 50mg (NDC: 49281-0575-15) in the coming weeks. Once that additional supply is distributed, we will not be receiving any additional doses of Beyfortus 50mg (NDC: 49281-0575-15) until Fall of 2024. All additional allocations of Beyfortus 50mg (NDC: 49281-0575-15) will be allocated to birthing hospitals across the State. Vaccine Coordinators at Birthing Hospitals will receive an email notification from the MIIS once the additional allocation is processed for their site. Expect the vaccines to arrive within two weeks of the email notification. The Vaccine Management Unit will also be reaching out to select provider sites that currently have Beyfortus 50mg (NDC: 49281-0575-15) in their MIIS inventory, to set up redistribution of a portion of those doses to birthing hospitals. Please note that if your site is contacted by the Vaccine Management Unit to redistribute your Beyfortus 50mg (NDC: 49281-0575-15) supply, we will ensure you are left with a minimum 20 doses.
The Department of Public Health has also been informed by the CDC that we will not be receiving any additional doses of Beyfortus 100mg (NDC: 49281-0574-15) until Fall of 2024. Beyfortus 100mg (NDC: 49281-0574-15) will not be redistributed at this time. However, please ensure that your site is following the prioritization guidance provided below in the HAN Health Advisory to maximize the impact of the limited doses of nirsevimab that are currently available. Due to the constrained supply, nirsevimab doses should not be wasted at provider sites and the product should only be drawn directly before administration to the patient. If your site anticipates not using all of your 100mg supply this season, please reach out to the Vaccine Management Unit so we may redistribute those doses to sites in need.
As a final reminder, you should not split or double doses to get to the correct dosage size. Providers should not vaccinate a baby over 5 kg with two doses of the 50 mg nirsevimab, to equal the 100 mg dose of nirsevimab or vaccinate a baby under 5kg with a half dose of the 100 mg nirsevimab product.
Additional Resources:
